
Loading, please wait...

Loading, please wait...

Researchers analyzed 26,729 colorectal cancer (CRC) survivors and found that 15% developed 4,453 multiple primary cancers (MPCs). The cumulative incidence was 22.5%, with a median follow-up of 6.4 years. Common MPCs included prostate, subsequent CRC, lung, hematological, and breast cancers. The overall risk of MPCs was significantly higher, and their incidence increased over time, highlighting the need for targeted surveillance.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Researchers analyzed 26,729 colorectal cancer (CRC) survivors and found that 15% developed 4,453 multiple primary cancers (MPCs). The cumulative incidence was 22.5%, with a median follow-up of 6.4 years. Common MPCs included prostate, subsequent CRC, lung, hematological, and breast cancers. The overall risk of MPCs was significantly higher, and their incidence increased over time, highlighting the need for targeted surveillance.
2 months ago

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today

A comprehensive scoping review synthesises evidence linking prenatal maternal mental health to long-term offspring neurodevelopment, evaluating neuroendocrine, inflammatory, and epigenetic pathways while highlighting clinical screening and future research priorities.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

A 25-year multi-institutional cohort reveals high recurrence rates in pediatric giant cell tumor of bone, particularly in patients with open physes and bone marrow edema on preoperative MRI. Early surveillance and careful balance between growth plate preservation and tumor clearance are essential.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today